Patients are often under the impression that chemotherapy drugs like Taxotere (docetaxel) and Jevtana (cabazitaxel) won’t significantly improve survival and will only dramatically impair quality of life. A patient once said to me, “That sounds like a bad deal.” I hope this issue of Prostapedia changes your view of chemotherapy.

The potential benefit of chemotherapy depends on where you are in the natural history of metastatic prostate cancer. If you have just been diagnosed with widespread metastatic prostate cancer, Lupron (leuprolide) plus Taxotere (docetaxel) can have a major benefit in terms of your survival. At this point, you are likely to tolerate chemotherapy better than you would if you had already been through multiple other treatments. However, even in patients who have been extensively treated before chemotherapy, this treatment can often provide significant relief of bone pain that outweighs the drug side effects.

In many other cancers, patients benefit greatly when we combine drugs. While the search for effective Taxotere (docetaxel)-based combinations has been going on for decades, no combination has survived rigorous Phase III testing. I, and many others in the field, think that this may be because prostate cancer is a very heterogeneous disease. The path to success requires that we understand at a molecular level the various forms of this disease and the key vulnerabilities of each variation. One example is the sensitivity of prostate cancers with a BRCA2 mutation to Paraplatin (carboplatin). Another example is the activity of Jevtana (cabazitaxel) + Paraplatin (carboplatin) in anaplastic prostate cancer.

There are several reasons to be optimistic about progress. First, research into the molecular heterogeneity of prostate cancer and the clinical implications thereof is proceeding rapidly. Second, leads that emerge from this research are being tested more rapidly and with greater sophistication than at any time in the past.

Charles E. Myers, Jr., MD

The information, products, and media advertised in Prostapedia are advisory only. Individuals pictured are models and are used for illustrative purposes only. Please consult your physician for specific medical or therapeutic advice.

Copyright August 2018. Rivanna Health Publications, Inc. All rights reserved. ISSN: 2381-4020

Prostapedia is published in Charlottesville, Virginia by Rivanna Health Publications, Inc.
There are very few people who don’t immediately panic when they hear that they’ve been diagnosed with cancer. Am I going to die, most wonder, even if they don’t voice that fear to their friends and family. Many patients have a similar reaction when their doctor suggests chemotherapy. But just as cancer itself is not always a death sentence, chemotherapy is not as bad as most think.

Chemotherapy for prostate cancer today is not your grandfather’s chemo. Most side effects are manageable and don’t stop men from going about their daily lives. And studies suggest that using chemotherapy earlier and not waiting until your disease has progressed has tangible benefits.

This month we take a deep dive into chemotherapy today. Dr. Ken Pienta frames this month’s discussions and points out that the cultural view of chemotherapy as catastrophic to the patient is largely unfounded.

Dr. Nicholas Vogelzang outlines the history of chemotherapy for prostate cancer and muses about future directions.

Dr. William Oh explains the role chemotherapy plays in a prostate cancer treatment today.

Dr. Cy Stein talks about side effects associated with Taxotere (docetaxel) and Jevtana (cabazitaxel) and how to manage them.

Dr. Oliver Sartor explains the development of Jevtana (cabazitaxel) for prostate cancer.

Dr. Emmanuel Antonarakis talks about the potential impact of switching from Taxotere (docetaxel) to Jevtana (cabazitaxel) midway through treatment and vice versa.

Dr. Channing Paller introduces her clinical trial looking at combining Taxotere (Docetaxel) with intravenous Vitamin C. She’s recruiting patients, so if you think you might be a fit for the trial, be sure to contact her.

Finally, both Mark Slaughter from Us Too! and Bill R. tell us about their experiences with chemotherapy for prostate cancer and their advice for men in similar situations.

The bottom line is that, if you’ve been prescribed either Taxotere (docetaxel) or Jevtana (cabazitaxel) for prostate cancer, there is no need to panic. Both drugs can have a dramatic impact on your survival, and their side effects can be managed with a little forethought and careful monitoring. Talk to your doctor about any concerns you have. Reach out to other men with prostate cancer who’ve had either of these medications. As with anything in life, the more you know going into the experience, the easier of a time you’ll have. Many times we fear the unfamiliar.

And, as always, be sure to share this issue of Prostatepedia with your doctor. Use these conversations as a jumping off point for an honest discussion. She may agree or disagree with some of the points made in the interviews that follow. Talking about why she is taking a certain approach with your disease will help you feel more comfortable with any decision that the two of you agree upon.

There has never been a better time to be a prostate cancer patient, friends. Your doctor has many tools in her wheelhouse to fight your cancer.
Dr. Kenneth J. Pienta, of the Johns Hopkins University School of Medicine, is an international expert in the development of novel chemotherapeutic agents for prostate cancer. He was the recipient of the first annual American Association for Cancer Research Team Science Award and is the author of more than 300 peer-reviewed articles.

He frames this month’s conversations about chemotherapy for us.

In 2018, chemotherapy for prostate cancer continues to be one of the many options we have to lengthen the lives of patients suffering from metastatic prostate cancer. There are still multiple other therapies that we don’t consider chemotherapy. Second-generation anti-androgen therapies like Zytiga (abiraterone), Erleada (apalutamide), and Xtandi (enzalutamide) are all now standards of care in castrate-resistant prostate cancer. We also have Xofigo (radium-223) as an option for patients with bony metastases.

There are two chemotherapies that have been approved for prostate cancer: Taxotere (docetaxel) and Jevtana (cabazitaxel). Now, the real challenge for patients and providers is when to use those chemotherapies.

Multiple studies have demonstrated that, when you’re newly diagnosed with metastatic prostate cancer, it may be beneficial to receive a limited number of doses of Taxotere (docetaxel) at the start of hormone therapy. That’s especially true if you have multiple places where the cancer has spread. That’s not correct for all people, but for some patients, it is a good option. More and more physicians are prescribing Taxotere (docetaxel) with a luteinizing hormone-releasing hormone (LHRH) antagonist at the start of therapy. However, that doesn’t mean you cannot use Taxotere (docetaxel) after other things have failed. If you failed second-line hormone therapy or have failed radium therapy, Taxotere (docetaxel) is still a good option that helps people live longer.

Jevtana (cabazitaxel) continues to be a good chemotherapy option if patients have failed Taxotere (docetaxel).

The chemotherapy we use for prostate cancer is really a single-agent chemotherapy, either Taxotere (docetaxel) or Jevtana (cabazitaxel). This is not the multi-agent therapy we use for other cancers, so the idea of major side effects is a bit overblown. For example, nobody vomits from chemotherapy for prostate cancer. The drugs we use to prevent that are too good. We also have gotten much smarter about limiting the number of doses we use. We don’t necessarily give chemotherapy until it doesn’t work anymore. Often, we just give several doses and then take a break. If you get more than a couple doses of chemotherapy, you will still lose your hair temporarily.

Chemotherapy can make you feel more tired when it lowers your blood count, and it can make you more susceptible to infections, but people are very rarely hospitalized now for an infection from chemotherapy. It’s virtually unheard of that somebody would die as a side effect of chemotherapy.

The major side effect of Jevtana (cabazitaxel) tends to be diarrhea, but again, as we’ve learned about the dosing of that drug, that has become more manageable. Another side effect of both drugs can be peripheral neuropathy, which is tingling in the fingers and toes. But we watch for that too. If you start to develop that, we tend to stop the drug. These are very tolerable medicines.

The word chemotherapy always evokes images of horror, but chemotherapy in 2018 is a lot different than it was even five years ago. We just know how to give chemotherapy much better.

Thank goodness we’ve seen over the last several years an increase in the number of drugs available to treat metastatic prostate cancer in addition to chemotherapy. Chemotherapy has been around for quite a while now, but there is still a role for it. Again, the challenge for all of us is: when do we slot them in for you?

The challenge is in what order are we going to use all these powerfully good drugs rather than having only one drug to give or none at all.

When I started in the field 30 years ago, if you had metastatic castrate-resistant prostate cancer, survival was 6 months. Now, with the advent of all these newer therapies, we’ve gotten much better. The landscape of how to treat prostate cancer has changed completely in the last five years. It will change completely again in the next five years. The challenge is in what order are we going to use all these powerfully good drugs rather than having only one drug to give or none at all.

For us as physicians, it’s an exciting time to take care of men with prostate cancer.
Nicholas Vogelzang, MD, The History of Chemotherapy for Prostate cancer

Dr. Nicholas Vogelzang is a medical oncologist at Comprehensive Cancer Centers of Nevada. He is a member of the 2018 Class of Giants of Cancer Care, a designation awarded to healthcare professionals advancing the field of oncology by their contributions in research and clinical practice.

He also serves as Associate Chair for the Genitourinary Committee of US Oncology, the Vice Chair SWOG GU committee, and the Associate Editor of Kidney Cancer Journal and Clinical Genitourinary Cancer.

Prostatepedia spoke to him recently about the development of chemotherapy for prostate cancer. He also offers advice for men prescribed chemotherapy and thoughts on a new class of drugs called PARP inhibitors.

What was it about medicine that drew you in?

Dr. Nicholas Vogelzang: I was raised in a very religious family. My dad was a pastor. We were seven kids. We’d go to church three times every Sunday and probably three times a week. Like a lot of Protestant families, the idea was that your chief aim in life was to glorify God and praise Him forever. The way you do that is by serving others. Out of the seven of us, there are three doctors, two nurses, and two CEOs. We did okay.

It was really all about service to others. Thus, medicine was a logical career. Fortunately, I had a decent brain, I could get along pretty well with people, and I was very much drawn to science. During my undergraduate and medical school years, I spent a fair bit of time in biology laboratories such as Argonne National Lab near Chicago. When I was in medical school, I was what the University of Illinois called a James Scholar, which allowed me to be fairly independent and again spend time conducting research. Researchers discover new knowledge by comparing the control (the old or standard approach) to the experimental (the new or potentially better approach). That training has served as a paradigm throughout my academic life.

When I started in my internal medicine career at Rush Presbyterian in Chicago, cancer was still in great need of better treatments. There had been some major advances that included the development of curative chemotherapy for childhood leukemia, Hodgkin’s Disease/Non-Hodgkin’s lymphoma, and testicular cancer, as well as development of chemotherapy that worked for some solid tumors of breast, lung, and colon cancer.

Yet, when I started to see prostate cancer patients in the late 1970s at the University of Minnesota, the assumption was that nothing really worked. Chemotherapy was declared as not worth doing for prostate cancer.

That always struck me as odd because there was virtually no cancer for which you could not find some chemotherapy drugs that would work. But that thinking was probably the result of the high effectiveness of hormone therapy for prostate cancer. It lulled everyone into complacency. These were older men. The hormone therapy worked. The cancer pain went away. The theory was that we shouldn’t give them a toxic medicine. That was the dominant paradigm.

There were a few voices in that wilderness of the 1970s. They were mostly urologists, interestingly. Gerald Murphy and Claude Merrin at Roswell Park used chemotherapy probably under the inspiration of James Holland, who was then at Roswell Park, and who developed chemotherapy along with Emil Frei and others at the National Cancer Institute (NCI) in the 1950-60s.

Dr. Murphy developed a whole series of early studies showing that chemotherapy had a clear but modest effect on metastatic hormone refractory or androgen independent prostate cancer in terms of decreasing pain and improving survival. Medical oncologists such as Chris Logothetis at MD Anderson, Alan Yagoda, Howard Scher, and Cora Sternberg at Memorial Sloan Kettering reported modest success as well.

Then there was a series of articles from my friends Derek Raghavan, Mario Eisenberger, and Ian Tannock in 1987-88 arguing that chemotherapy had no role in the treatment of prostate cancer.

It was yin and yang. One study would show that maybe there’s some benefit. And then another showed that you’re just harming the patients.

As I became a faculty member at University of Chicago in 1982, I was responsible for developing drugs for these patients, and it became clear that chemotherapy did, in fact, work. It wasn’t common, but you could have dramatic effects in patients for whom hormone therapy had stopped working.

I remember five or six of my patients in the mid 1980s who were in terrible pain and had dramatic responses. One patient got dramatic that I wrote up a case report. Thus, I became a member of the camp that encouraged chemotherapy use.

Then, along came Novantrone (mitoxantrone), a drug that was well tolerated and improved pain in a good number of patients. We ran two large studies. The group that I was leading at the time, called the Cancer and Leukemia Group B (CALGB), did one study. The Canadians, led by Ian Tannock, did the other one. Both showed a reduction in symptoms and a modest reduction in cancer activity—not much, but some. Those studies led the FDA to approve Novantrone (mitoxantrone) in 1996.

We had a lead from a laboratory run by Willie Kreis of Long Island Jewish Medical Center. Dr. Kres told the CALGB members that this drug called Taxotere (docetaxel) was very effective against prostate cancer cells growing in the lab. CALGB members, with the concurrence of the NCI, voted to do a Phase II trial led by Diane Sarseroe. Taxotere (docetaxel) had been approved for breast cancer. It made sense that it would work for prostate cancer. In that trial, we saw a lot of patients for whom the drug worked.

We looked back at our CALGB Novantrone (mitoxantrone) data and compared it to the Taxotere (docetaxel). Docetaxel appeared better able to reduce PSA and to reduce pain. Moreover, patients were living three to four months longer than we would have expected.

After a series of meetings with the NCI and Sanofi, the drug’s manufacturer, the decision was made to do two major studies. Sanofi did one study led by Dr. Tannock and the Southwest Oncology Group (SWOG), led by Dr. David Crawford and Dr. Daniel Petrylak. CALGB did the other. In both cases, we compared Taxotere (docetaxel) to Novantrone (mitoxantrone).

We wanted to make certain that everyone got Novantrone (mitoxantrone) so patients were allowed to cross over, which means that if you were randomized to Novantrone (mitoxantrone), you could get Taxotere (docetaxel) second or vice versa. It was an easy study to do.

Both of those studies were reported at the American Society of Clinical Oncology (ASCO) Plenary Session in 2003. That was the biggest, most prestigious conference that the present cancer research in the world. Both studies showed longer life, better pain control, higher rates of PSA decline, and shrinkage of the lymph nodes with Taxotere (docetaxel) compared to Novantrone (mitoxantrone).

The FDA approved Taxotere (docetaxel) based on those studies. Finally, after so many years, we had two drugs for prostate cancer. Recall that breast cancer had about 10 drugs approved at that time.

The next step came with a drug called Platinol (cisplatin). Platinol (cisplatin) had been developed in the 1970s, and it was very active for testicular, ovarian, lung, bladder, and other cancers. Everybody wanted Platinol (cisplatin) to be useful for prostate cancer, but it was pretty toxic, particularly for older men.

A less toxic carboplatin had some activity and is commonly used today but never gained FDA approval.

A company came up with a non-toxic formulation of Platinol and conducted a 900-patient trial that went all the way to the FDA. Unfortunately, the FDA said the drug was not good enough to approve. It was very disappointing.

At the same time, Sanofi was developing a drug similar to Taxotere (docetaxel) that overcame some of its side effects: no hair loss and less nerve damage. They compared it to Novantrone (mitoxantrone), but this time, after Taxotere (docetaxel) had stopped working. As reported by Drs. Oliver Sartor and Johann de Bonno, that drug improved survival, and that drug was Jevtana (cabazitaxel).

Recently, it was compared directly to docetaxel but did not improve survival as compared to docetaxel.

In 2018, now we have three FDA approved drugs for castrate-resistant prostate cancer: Novantrone (mitoxantrone), Taxotere (docetaxel), and Jevtana (cabazitaxel).
and Jevtana (cabazitaxel). It only took us 25 years to get them! That’s really where we are today. We still don’t have approval of Platinol, although everybody uses it because it works great for some patients.

There are certain other drugs that might be effective. We still use drugs like Toposar (etoposide) and Gemzar (gemcitabine). They’re old now. No company will get behind their development anymore. They’re no longer under patent. You can’t really get much traction to get them through clinical studies. A drug called suramin had activity, but was abandoned without going to the FDA.

The platinum class of drugs has now been identified as being active in the small percentage of prostate cancer patients with DNA repair mutations, about 15-20 percent.

When we were studying the platinum drugs, we knew that some of the patients did really well, but we didn’t know how to find them. Now, we think we know that those patients who do well on platinum have mutations in DNA deficient repair (DDR) enzymes. Some of the DDR mutations include genes such as BRCA-1, BRCA-2, ATM, FANC, and CHEK-2, which cause prostate cancer in men and breast and ovarian cancer in women. We now want to go back and do studies of platinum in these DDR mutation patients.

I use platinum routinely for patients and find a lot of success after patients fail on Taxotere (docetaxel) or Jevtana (cabazitaxel). So, though platinums are not FDA approved, we have four drugs.

Do you have any advice for men who have been prescribed chemotherapy?

For many patients, it’s a frightening thing. There’s a cultural concept that chemotherapy is terrible. I understand how seriously patients take this issue, although it’s an unfounded fear.

I have a patient who is dying. He’s a retired pilot. He refused to take chemotherapy. Yet, he went to the Philippines and spent $30,000 on some herbal potion rather than go on chemotherapy. He came back far worse than when he left. At this point, he’s trying chemotherapy, but he’s just taken too long to get it.

There are a couple of things I’d say. Number one: don’t wait too long. Take chemotherapy when you’re strong.

Number two: all the side effects are reversible. You don’t suffer the whole time, although fatigue is real. You’ll have nausea for a day and some folks get bad diarrhea. We have developed dramatically effective drugs to prevent diarrhea, nausea, and vomiting. You don’t vomit anymore. You may not even get nauseated. About the only thing you get is fatigue. Taxotere (docetaxel) can cause hair loss, but Jevtana (cabazitaxel) does not.

If you use an ice cap, like women do with breast cancer, you don’t lose your hair. You can get some numbness in the fingers, but you can prevent that by using ice on your hands. There’s even a product on the market now, called the cold cap, that you can buy for $300 or so that you wear on your head. It looks like a World War I flying cap from the Red Baron. You put it on your head during the one hour of chemotherapy. It virtually prevents the hair loss.

There are also mittens and stockings that protect against fingernail and nerve damage in the hands and feet. You can do it the inexpensive way and put your hands and feet in ice. People come into my clinic and ask what all those guys are doing with their feet in ice? It’s to prevent nerve damage from the chemotherapy.

Like I said, Jevtana (cabazitaxel) avoids those side effects. I try to give Jevtana (cabazitaxel) whenever I can first for that reason. Usually, the insurance requires Taxotere (docetaxel) first because Jevtana (cabazitaxel) is a lot more expensive.

Jevtana (cabazitaxel) can be really well tolerated for a long time. I have one patient who is a rancher originally from Minnesota. He is on dose number 27 of Jevtana (cabazitaxel). His PSA started in the high hundreds and now it’s 11. In some patients, chemotherapy is highly effective, long lasting, and is clearly not to be feared.

It’s just urban legend that somehow chemotherapy is bad. We figured out many years ago that chemotherapy is not to be feared.

Is there anything else you’d like patients to know?

Dr. Vogelzang: New drugs called PARP inhibitors are coming. These are oral drugs with effects like chemotherapy. They’re being developed for patients with DDR mutations. We’re beginning to use those drugs more and more. They will cause low blood counts and mild anemia. Some of the side effects are similar to what we see with chemotherapy, but because they’re oral medications, most men don’t have as much fear of them. Five are in development. I think we’re going to see one or two of them hit the market in the next year or two.
William Oh, MD
Chemotherapy for Prostate Cancer

Dr. William Oh, of the Mount Sinai Medical Center and the Icahn School of Medicine at Mount Sinai in New York City, is a medical oncologist and expert in the management of prostate, renal, bladder, and testicular cancers.

Prostatepedia spoke with him about the role chemotherapy plays in prostate cancer treatment strategies.

Why did you become a doctor?

Dr. William Oh: I have always enjoyed interacting with people. Before I became a doctor, I didn’t really understand how important the personal relationship with patients could be for my own wellbeing, but it has turned out very much to be that way. From the time I was a child, many of my role models were doctors, such as my own pediatrician.

The healing aspect is what drew me to medicine. But after becoming a doctor, I’ve enjoyed the science to a great extent, especially in oncology.

Have there been any patients who changed how you see your role?

Dr. Oh: I have many patients, of course, but certain patients always stand out in your mind.

When I was a medical student at Bellevue Hospital, a big city hospital, I was just learning how to draw blood at a time when medical students still drew blood. I remember I was sent into an IV drug user’s room to draw his blood. He was particularly difficult to draw blood from, but he couldn’t have been nicer and more patient with me. He was a relatively young guy, and he was trying to help me. “Doc,” he said, “try this vein.” This was a person who I would have never interacted with in my life, and yet, there he was. We had a shared mission: to help him, I needed to draw his blood.

It really opened my eyes to the physician-patient relationship. Many, many times since then, with patients from all different walks of life, I find the common threads of humanity. It sounds cliché, but that is really what medicine is about. A person who is sick—it doesn’t matter how much money they have, what their race is, or their education—they all want to be taken care of.

What types of chemotherapy are available to prostate cancer patients today?

Dr. Oh: In many ways and for many patients, chemotherapy has a negative reputation. People tend to lump all chemotherapy drugs together, but it’s very important to remember that there are hundreds of kinds of chemotherapy. The word chemotherapy really just means chemical therapy for cancer, but that’s not the same thing for everyone.

There are two major chemotherapy agents approved and commonly used in prostate cancer. Taxotere (docetaxel) and Jevtana (cabazitaxel).

When Taxotere (docetaxel) was first approved in 2004, it was really an important milestone because up until that point, there were no drugs of any kind that were proven to improve survival in metastatic prostate cancer.

Taxotere (docetaxel) showed that it could be done. Then it took many years of research and clinical trials to get to the next set of drugs that improved survival, especially in castrate-resistant prostate cancer. These include drugs like Zytiga (abiraterone), Xtandi (enzalutamide), Provenge (sipuleucel-T), and Xofigo (radium 223).

Since 2004 with the approval of Taxotere (docetaxel), we still think improving survival is the most important goal for patients with advanced prostate cancer. As an oncologist, I felt the survival improvement is—for most patients—worth the side effects patients may have. This is a critical point, because many people think that chemotherapy has terrible side effects and doesn’t do anything of value. That is not a fair stereotype. While it does have side effects, and it doesn’t always work, in many ways, chemotherapy has great value for our patients in terms of improving both their survival and their quality of life.

The perception is definitely that the side effects of chemotherapy can be terrible, so how might chemotherapy improve quality of life?

Dr. Oh: When we first started giving chemotherapy for metastatic disease (and still today), patients were often very symptomatic. They had a short expected lifespan, and they were in pain. They were weak. They couldn’t walk. They would have a lot of side effects from cancer. The way that drugs like chemotherapy can boost quality of life is that, by shrinking the cancer—by directly killing cancer cells, we can make patients feel better. If they have fatigue or some hair loss from chemotherapy, that wasn’t something they wanted, but they could be in a much worse state from the cancer itself. They were really suffering from it.

In balance, the chemotherapy was able to make them feel better by reducing their pain medication requirements and by improving their functionality and their appetite. We often see that.

When chemotherapy works—and it’s not always—it can really shift a person’s quality of life, and it also improves their duration of life. These are the two critical factors for any cancer drug.

When is a patient likely to encounter Taxotere (docetaxel) and Jevtana (cabazitaxel)? Why would your doctor choose one over the other?

Dr. Oh: When docetaxel was first approved, it was approved for metastatic castrate-resistant prostate cancer (CRPC). In that state, it had a relatively modest survival benefit on average. But for individual patients, it could have a dramatic benefit. We always thought, why wait till the patients develop CRPC? If we use it earlier, would it have a greater impact?

In 2015, the CHAARTED and STAMPEDE studies (see https://www.nejm.org/doi/full/10.1056/NEJMoa1502747) showed that early use of Taxotere (docetaxel) chemotherapy in men with newly diagnosed metastatic disease could have a very profound improvement on survival. In other words, rather than waiting for the cancers to become resistant to hormone treatments, if you used hormones with chemotherapy right up front—six cycles of Taxotere (docetaxel)—you could have a more dramatic improvement in overall survival. That changed the standard of care for hormone naive Taxotere (docetaxel) chemotherapy. Now it’s an option for patients when they’re newly diagnosed with metastatic disease.

Jevtana (cabazitaxel) was approved in 2010 based on the TROPIC study in patients who had already received first-line Taxotere (docetaxel). Jevtana (cabazitaxel) is currently a second-line chemotherapy agent. It does have a different set of side effects compared to Taxotere (docetaxel). For example, patients are less likely to lose their hair.

As in Erleada (apalutamide) or Xtandi (enzalutamide), the drugs work by inhibiting the microtubules that allow cancer cells to grow rapidly. Jevtana (cabazitaxel) was approved because, even in patients who had already received Taxotere (docetaxel), Jevtana (cabazitaxel) improves survival and may be an important second chemotherapy agent for patients for receive after they’ve already received Taxotere (docetaxel).

Dr. Oh: Generally, chemotherapy is not used in combination with other drugs because usually these drugs are given in sequence. Whether this is the correct way to do it or not is not 100 percent clear.

There are ongoing research studies to see if they can be combined safely rather than given in sequence because they may have an additive or synergistic benefit if you combine, for example, a chemotherapy drug with an androgen-receptor targeted therapy or with a bone-targeted therapy.

As in Erleada (apalutamide) or Xtandi (enzalutamide), chemotherapy or with a bone-targeted therapy?

Dr. Oh: Exactly.

What should men know if they’ve been prescribed one of these drugs?

Dr. Oh: Try not to have an uninformed ‘gut reaction’ to chemotherapy, or their education—they all want to be taken care of.
We know that chemotherapy may be less targeted than other drugs, but cancer cells are tricky and they often learn how to mutate and change. Chemotherapy can knock out many different kinds of cancer cells. That may be one of its advantages. It works differently than androgen-receptor therapy, immunotherapy, and bone therapy. Men should understand that chemotherapy is a very important option, especially when the cancer has become more aggressive.

For the most part, the side effects are manageable, right? It’s not like some of the side effects of immunotherapy, which can be really devastating.

Dr. Oh: I think side effects from all of these drugs can be manageable for most men, and that includes chemotherapy, immunotherapy, and androgen-targeted therapy.

Readers may not know this, but some of my patients tolerate chemotherapy better than they tolerate some of the androgen-targeted therapies. Androgen-receptor blockade with drugs like enzalutamide or abiraterone can be really life-altering for some patients.

For some patients, chemotherapy is easier. It sounds paradoxical, and it’s not always true, but each person responds differently. On average, the chemotherapy side effects are manageable. There are drugs to manage them, but you can adjust the dose and you can still get the benefit of the treatment if you have an experienced oncologist helping to manage the use of chemo.

Is there anything else men should know?

Dr. Oh: There are some exciting data regarding the use of an old chemotherapy that may have a new application, namely Paraplatin (carboplatin). It has been around for 30 to 40 years, but it may work specifically in tumors that have DNA repair abnormalities like BRCA2 mutations.

Even in the era of precision medicine, patients with BRCA-mutated cancers may benefit more from a drug like Paraplatin (carboplatin) chemotherapy. We know that Paraplatin (carboplatin) can be given, for example, with a drug like Taxotere (docetaxel) quite safely. Those kinds of combinations may be right for some patients if they have a DNA repair abnormality such as BRCA2.

That’s really interesting. Do you think it’s likely that there are other genetic mutations for which certain agents will be particularly useful? That this is just the beginning of that story?

Dr. Oh: This is absolutely the beginning of the story. We have failed to understand what drives each individual tumor. It feels overwhelming to think that each cancer is a little different from the others. But we’re going to start to develop individualized treatment plans for patients based on the kind of tumors they have. We have used a one-size-fits-all approach so far, which is the wrong approach for many cancers.

Chemo will remain part of the solution; it just may not be given to everyone the way it has been in the past.
Cy Stein, MD
Chemotherapy
Side Effects

Dr. Cy Stein is a medical oncologist at California’s City of Hope hospital. He routinely advises his fellow doctors to, “Never think about yourself. It’s only about the patient.”

Prostatepedia spoke with him about dealing with the side effects of chemotherapy for prostate cancer.

Why did you become a doctor? What was it about medicine that drew you in? What keeps you there?

Dr. Cy Stein: Why did I become a doctor? That’s a very complicated question. It all started a long time ago. It caught my interest when I was a very young fellow, and it was my ideal throughout high school. Then I got hooked on chemistry when I went to college. I wound up with a PhD in Chemistry. I decided, very early on in the course of that study, that I really shouldn’t try to pursue chemistry as a career. I should stick with medicine, which was more my inclination. Medicine was more broadly humanistic than chemistry ever could be, although chemistry is a wonderful science, and I enjoyed it very much.

What kept my interest in medicine was chemotherapy. Chemotherapy seemed to be a very good way of continuing my interest in chemistry.

In those days, chemotherapy was what was used to treat cancer. Things are more sophisticated now, but it was virtually all chemotherapy.

Cancer was a great unmet challenge, and people were suffering terribly from it. I felt that if you had the ability to do something about it, you should put yourself out there and try.

What are the most common chemotherapy drugs that men with prostate cancer are likely to encounter today?

Dr. Stein: It all depends on what your definition of chemo is, but I take a very narrow definition that I think most of the community would take.

There are two chemotherapy drugs that exist for prostate cancer. One of them is called Taxotere (docetaxel). The other is Jevtana (cabazitaxel).

I don’t consider drugs like Lupron (leuprolide) to be chemotherapeutic agents. We consider them to be hormonal agents because they act directly on testosterone. Testosterone, as I’m sure everybody knows, is the male sex hormone. In order to get responses in prostate cancer, physicians have to lower the patient’s level of testosterone in their blood. That’s not a chemotherapeutic way of doing it; that’s a hormonal way of doing it. Similarly, the newer drugs that have come out recently are not chemotherapeutic agents either. I’m referring to Zytiga (abiraterone) and Xtandi (enzalutamide). We call them oral hormonals. Provenge (sipuleucel-T) is a kind of tumor vaccine, so it’s really immunologic oncology. Xofigo (radium 223) is also not a chemotherapeutic agent, so we’re down to two.

What are the differences between the two. When would Taxotere (docetaxel) be used over Jevtana (cabazitaxel)?

Dr. Stein: Taxotere (docetaxel) was first developed in 1995-1996 and has been on the market for a long time. It was originally used in breast cancer and lung cancer as well. Then it was introduced for use in prostate cancer.

There is significant amount of toxicity with Taxotere (docetaxel), although it is a very good drug. It is different...
from Jevtana (cabazitaxel), even though both of the drugs are formed to the same general class of molecule, which we call taxanes. They both come from, ultimately, the needles of the Pacific Yew tree.

Even though the names sound similar, these are different drugs with different toxicity profiles. The important thing for a patient to remember is that, even though these drugs have side effects, at times we see spectacular responses from both of them. The side effects are manageable and definitely worth the effort for the patient because of the potential for the response that you can get.

Taxotere (docetaxel) has more side effects than Jevtana (cabazitaxel). Taxotere (docetaxel) seems to have more toxicity, and most important, the toxicity seems to get worse as patients age. Therefore, I find it extremely difficult, if not impossible, to give Taxotere (docetaxel) to men who are over 80.

What toxicities are we talking about?

Dr. Stein: For Taxotere (docetaxel), the major dose-limiting toxicity is fatigue. People are not going to feel anything on the day that they get the Taxotere (docetaxel). The day after, they’re going to feel pretty tired, and most men will want to just stay in bed. Their partners don’t particularly like that, but it’s probably best to leave them in bed because they’re not going to be very functional for a day or more on Taxotere (docetaxel).

It’s not uncommon for a man to say, “For three days after I get this drug, I’m very wiped out.” I’ve even heard them say, “Five to seven days after I get this drug, I feel very wiped out.” Then the men will get better, and eventually they will come back for their next cycle, and we’ll do it all over again. It doesn’t happen quite so much with Jevtana (cabazitaxel) because it is a little easier on the fatigue.

In terms of other side effects, one of the side effects that Taxotere (docetaxel) has, only in about 10% of cases, is febrile neutropenia. That is the white blood cell count goes down seven to nine days after getting the chemotherapeutic drugs and leads to an infection. The patient will have a fever of 100.4 or greater, and the febrile neutropenia requires antibiotics. With Jevtana (cabazitaxel), the incidence of febrile neutropenia is much, much higher. What I do is make sure that all of my patients who have Neulasta (pegfilgrastim) applied before they get the chemotherapy, to prevent their white count from going down.

Getting febrile neutropenia on Jevtana (cabazitaxel), so I treat every one of my patients who have Neulasta (pegfilgrastim) applied before they get the chemotherapeutic drugs, to prevent their white count from going down.

There are some patients who may not need Neulasta (pegfilgrastim), but “I want the drug.” He got it. I prefer to sleep calmly at night. I don’t want to worry about a patient getting febrile neutropenia on Jevtana (cabazitaxel), so I treat every one of my patients with Neulasta (pegfilgrastim).

In terms of other toxicities, many men say that Taxotere (docetaxel) also causes food to taste like cardboard. Their hair will certainly thin, but it probably won’t all fall out. They may get tearing of the eyes. They may get changes in their nails such as brown bands that horizontally cross the nails. These disappear after discontinuation of treatment. They can also, potentially, get a little bit of fluid in their lungs, although in my experience that hasn’t been a clinical problem. They can also, potentially, develop neuropathy.

It sounds rough, and for some men it is, but a lot of men go through it very well. They can have a tremendous response. I’ve seen any number of individuals have responses of 75% and even 90% in their PSA. These are the kind of individuals who live a great deal longer than if they didn’t respond. Jevtana (cabazitaxel) is a very similar story, except the fatigue is much less. The neuropathy is significantly less, although I have seen patients with neuropathy on Jevtana (cabazitaxel).

Dr. Stein: For Taxotere (docetaxel), the full dose is 75 mg/m². There’s little evidence that you lose much in the way of efficacy if you go to 50 mg/m² to avoid toxicity, and I’ll do that frequently.

Is there anything men can do to prepare themselves for these side effects?

Dr. Stein: Aside from communicating with their doctors and taking Claritin if you’re receiving Neulasta (pegfilgrastim), I’m not sure there is anything you can do.

Is there anything else you’d like patients to know about chemotherapy for prostate cancer?

Dr. Stein: These are very realistic options for patients. Men can tolerate Taxotere (docetaxel) for maybe six to eight cycles. It’s hard for men to get more. With Jevtana (cabazitaxel) it’s unbelievable how much people can get because the toxicity is less. I know of a man who received 55 continuous cycles of Jevtana (cabazitaxel) and did extremely well. My own personal record is 33 cycles. In one of those cases, the patient had a 99% response in his PSA; he lived three extra years. He did extremely well.

I had another man who also got 33 cycles. His PSA was roughly 50 to 70 and it stayed that way for 33 cycles before he started to progress. I have seen quite a few remarkable responses.
The Development of Jevtana (Cabazitaxel)

Dr. Oliver Sartor, the Laborde Professor of Cancer Research in the Medicine and Urology Departments of the Tulane School of Medicine, is one of the leading researchers in advanced prostate cancer today. He is also the editor-in-chief of Clinical Genitourinary Cancer and the author of more than 300 scientific papers.

Prostatepedia spoke with him about Jevtana (cabazitaxel) for prostate cancer.

How have you managed to keep some of the patients who might need it? Was there a particular case that changed your role as a doctor or how you approach the art of medicine?

Dr. Sartor: In 2010, the TROPIC trial indicated effectiveness with Jevtana (cabazitaxel) as a monotherapy, although it was given in combination with prednisone.

The use of additional agents has been something that many others have explored, and in particular, in combination with Paraplatin (carboplatin). Before the approval of Jevtana (cabazitaxel), we were exploring Paraplatin (carboplatin) combinations. We published articles on this back in 2009, or so, using combinations of taxanes, predominantly Taxotere (docetaxel) and Paraplatin (carboplatin).

We found that a subset of men could really have outstanding responses to the combination.

When, along the patient journey, are men likely to encounter Jevtana (cabazitaxel)?

Dr. Sartor: Today, in 2010, Jevtana (cabazitaxel) is FDA-approved in the post-Taxotere (docetaxel) space. Most people utilize it in that space. Men have to be fit enough to take chemotherapy—not all men are—and they have to have adequate bone marrow function. Jevtana (cabazitaxel) is one of the treatments that we consider for a wide variety of men in the post-Taxotere (docetaxel) space.

Is Jevtana (cabazitaxel) usually used alone or with other agents or treatments?

Dr. Sartor: Jevtana (cabazitaxel) is chemotherapy. It’s part of the taxane class. It has similarities and distinctions from the taxanes that people might be more familiar with, such as Taxotere (docetaxel) or paclitaxel.

Jevtana (cabazitaxel) was FDA approved in 2010. I was the co-Principal Investigator on the pivotal study and senior author on the Lancet manuscript for the TROPIC trial that led to FDA approval. The trial was designed to look at men who progressed after prior Taxotere (docetaxel) therapy.

At the time that trial was run, Taxotere (docetaxel) was the only known agent effective in prostate cancer. The trial showed that Jevtana (cabazitaxel) prolonged survival modestly, which gave men who had progressed after the known therapies available at that point additional hope.

When, along the patient journey, are men likely to encounter Jevtana (cabazitaxel)?

Dr. Sartor: Today, as in 2010, Jevtana (cabazitaxel) is FDA-approved in the post-Taxotere (docetaxel) space. Most people utilize it in that space. Men have to be fit enough to take chemotherapy—not all men are—and they have to have adequate bone marrow function. Jevtana (cabazitaxel) is one of the treatments that we consider for a wide variety of men in the post-Taxotere (docetaxel) space.

Today, we commonly use a Jevtana (cabazitaxel) and Paraplatin (carboplatin) combination. Occasionally we get really rewarding responses.

What are the side effects like for Jevtana (cabazitaxel) when alone and when used in conjunction with other agents?

Dr. Sartor: We have a really good handle on the side effects now. We ran a head-to-head comparison of Jevtana (cabazitaxel) and Taxotere (docetaxel) as part of a large trial called FIRSTANA. I was the senior author of that manuscript, published in the Journal of Clinical Oncology (UCO) last year. With each dose of Jevtana (cabazitaxel) and one dose of Taxotere (docetaxel), we found that there was more myelosuppression—more bone marrow suppression—than in those who received Jevtana (cabazitaxel) and less neuropathy.

In my experience, people tolerate Jevtana (cabazitaxel) better than Taxotere (docetaxel). There seems to be less edema, less neuropathy, and probably fewer naibed changes and alopecia (tacky word for hair loss). We’ve found it to be well-tolerated.

Today, we understand that better, mechanistically, and it may be due to the underlying presence of DNA repair defects. We, and others, have published on the responsiveness of patients who have mutations within DNA repair genes, especially BRCA-2. In that context, patients can have very rewarding responses with a combination of a taxane and Paraplatin (carboplatin). That accounts for probably somewhere around 25 percent of all patients. There may be additional patients who can benefit outside of those with DNA repair defects.

Today, we usually combine a Jevtana (cabazitaxel) and Paraplatin (carboplatin) combination.

That’s important for men.

Dr. Sartor: Absolutely. It’s critically important. And for doctors too. If we can manage the patient in a similar way, we can get similar outcomes and less toxicity, then we’re achieving the goals that doctors and patients share: therapy with fewer side effects.

What else should men know about Jevtana (cabazitaxel)?

Dr. Sartor: Men are inevitably attracted to non-chemotherapeutic approaches because they are generally less toxic. At times, the very best choice for a patient involves a chemotherapy approach, so Jevtana (cabazitaxel) could be an effective option, even when hormones have failed. It’s good to keep that option open.

When people refuse chemotherapy, they’ve closed off an option that could potentially be critical for their health. Men need to be open to all of the possible lines of treatment.

There’s a cultural prejudice against chemo. It seems wrapped up in the belief that cancer is always a death sentence; if you have chemo, you’re just going to lose your hair and feel sick. But that’s not necessarily true, right?

Dr. Sartor: I understand where that comes from. For many years, we got into a mode of giving more chemotherapy, believing it would be better. But it’s just not. There are limitations to chemotherapy and its effectiveness. Sometimes, a gentler dose can have the same degree of positive effects with less of the adverse ones.

I’m a better doctor today than I was 20 years ago. One of the reasons is that I understand how to give all my agents in a manner that is both safe and more cost-effective while preserving the positive effects on any cancer progression.

We’ve worked hard to try to get better. We’ve learned how to manage chemotherapy and its side effects.

By the way, the same concept of lower dosage is true for Taxotere (docetaxel). I give docetaxel today differently than how I gave it ten years ago. Today, I use a 50mg/m² every two weeks and have found it to be much more tolerable than the older 75mg/m² every three weeks. It’s interesting to me how I can give the same drug in a slightly different manner to make it much more attractive to patients who translate into potential increased effectiveness because we’re not fighting the toxicities like we used to.

Life is all about balance. And it’s good for men to know that physicians—at least the good ones—are doing their best to balance the toxicities and achieve the maximum benefits. That is a high priority for every good physician.
Emmanuel Antonarakis, MD
Switching from One Chemo Drug to Another

Dr. Emmanuel Antonarakis is an Associate Professor of Oncology and Urology at the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center.

Prostatepedia spoke with him recently about his work on the benefit of switching men from Taxotere (docetaxel) to Jevtana (cabazitaxel)—or vice versa—if his PSA doesn’t go down by 30% in the first twelve weeks of treatment.

“Here are many patients who have caused me to reconsider or change the way that I think about medicine.”

Dr. Emmanuel Antonarakis: There are many patients who have caused me to reconsider or change the way that I think about medicine. One particular example was a patient who was found to have a BRCA-2 mutation. I know that you guys are all very excited about this gene mutation and it sounds so futuristic and cool and exciting, but right now I don’t think I want to have any therapy at all.

He is still in his home country and will come back in about three months to see me again. At that time, he will decide whether he wants to do the trial, which might still be available.

It made me realize that sometimes the goals that we as academic physicians have and the goals that our patients have might be different. We all want our patients to live as long as possible and have the highest quality of life for as long as possible. For me as an academic investigator, I was excited by the prospect that I could offer this guy genetically targeted therapy but he didn’t really want treatment at that particular point in time. His main purpose was visiting his family in his country of origin.

That was a lesson for me. Our goals might not always overlap, but we should always respect our patients’ goals and be willing to view things in a different light. Different people have different attitudes about treatment and cancer and life.

Dr. Antonarakis: Exactly.

We’ve published a paper on switching patients from Taxotere (docetaxel) to Jevtana (cabazitaxel), and vice versa. What is the thinking behind switching chemotherapeutic agents? Why would you want to switch agents earlier as opposed to when the first chemotherapy drug stops working?

Dr. Antonarakis: The motivation behind this paper was that the FDA-approved recommended dosing schedule for both Taxotere (docetaxel) and Jevtana (cabazitaxel) is a course of ten doses, given three weeks apart. When patients begin FDA-approved Taxotere (docetaxel) or FDA-approved Jevtana (cabazitaxel), they’re often told by their oncologists that they should expect to receive this chemotherapy every once for up to ten doses. A patient may not receive ten doses or might stop the therapy before he reaches ten doses because he cannot tolerate the therapy and has unmanageable side effects, or his cancer begins to progress before he ever gets to dose number ten. If his PSA begins to increase again at dose six or seven or the tumors begin to grow again, his oncologist might ask him to stop chemotherapy.

“I’ll just sit on this for now.” And then he said something like, “Thanks, but no thanks.”

The patient turned around and said, “Well you know what I know that you guys are all very excited about this gene mutation and it sounds so futuristic and cool and exciting, but right now I don’t think I want to have any therapy at all.”

He is still in his home country and will come back in about three months to see me again. At that time, he will decide whether he wants to do the trial, which might still be available.

Dr. Antonarakis: Exactly.

The idea that we had was to test an early intermediate marker of sensitivity or resistance to the chemotherapy.

The best marker of early sensitivity or resistance that we could think of was whether or not a patient had a 30% PSA drop within the first four cycles of therapy. As you recall, if the therapy is given once every three weeks, four cycles basically means 12 weeks, which roughly equates to about three months.

The decision to use this intermediate endpoint was not arbitrary; it was based on some large retrospective meta-analyses that have shown that the strongest predictor of overall survival in prostate cancer is the PSA response, which was defined as a 50% or more decrease, was higher than patients who don’t achieve that endpoint. We thought, well if this endpoint is strongly correlated to survival, perhaps we can use it as a decision point. If after four doses of therapy or 12 weeks of therapy a patient doesn’t achieve a 30% reduction in PSA perhaps we should switch him to the other chemotherapy, rather than sticking with what we had just waited for either the toxicity to develop or the PSA or the radiographic disease to progress.

That was the hypothesis.

We designed a relatively small study of about 63 patients. We used a 1:1 randomization so they were twice as likely to get Taxotere (docetaxel) compared to Jevtana (cabazitaxel). Approximately 41 patients got Taxotere (docetaxel) first. The other 22 patients got Jevtana (cabazitaxel) first. Irrespective of which arm they were randomized to, they received the first four doses of chemotherapy in 12 weeks. We checked their PSA every three weeks.

At the end of the fourth dose, if the PSA level had dropped by 30% or more, the patients would continue on the same therapy on which they started. However, if patients did not achieve a 30% reduction or more, they would be switched to the other chemotherapeutic agent.

If a patient had a 25% reduction, we would switch him to the other agent because we thought that was not good enough. If someone received Taxotere (docetaxel), and their PSA dropped by 25%, it did not meet that 30% threshold so they would then switch for the fifth dose to receive Jevtana (cabazitaxel) for the remainder of their chemotherapy.

The interesting thing that we found in both treatment arms was that the chance that a patient had a favorable PSA response, which was defined as a 50% or more decrease, was higher than we had seen in historical trials using each drug by itself without switching.

To put some numbers on that, we found that there was about a 54% chance that patients would have a 50% reduction in PSA if they had to the opportunity to switch from one chemotherapy to the other, compared to about a 45% chance of PSA reduction in the historical data where patients did not switch.

“Some patients might potentially benefit from a switch strategy.”

We then wondered whether the ten doses was a reasonable time to wait or whether there could be an early indicator, or an early sign, of therapy resistance or therapy futility without having to go through six, seven, eight, nine or ten doses.

The patients who do achieve at least a 30% or greater reduction in the first 12 weeks have a survival that’s longer than patients who don’t achieve that endpoint. We thought, well if this endpoint is strongly correlated to survival, perhaps we can use it as a decision point. If after four doses of therapy or 12 weeks of therapy a patient doesn’t achieve a 30% reduction in PSA perhaps we should switch him to the other chemotherapy, rather than sticking with what we had just waited for either the toxicity to develop or the PSA or the radiographic disease to progress.

That was the hypothesis.

We designed a relatively small study of about 63 patients. We used a 1:1 randomization so they were twice as likely to get Taxotere (docetaxel) compared to Jevtana (cabazitaxel).

Approximately 41 patients got Taxotere (docetaxel) first. The other 22 patients got Jevtana (cabazitaxel) first. Irrespective of which arm they were randomized to, they received the first four doses of chemotherapy in 12 weeks. We checked their PSA every three weeks.

At the end of the fourth dose, if the PSA level had dropped by 30% or more, the patients would continue on the same therapy on which they started. However, if patients did not achieve a 30% reduction or more, they would be switched to the other chemotherapeutic agent.

If a patient had a 25% reduction, we would switch him to the other agent because we thought that was not good enough. If someone received Taxotere (docetaxel), and their PSA dropped by 25%, it did not meet that 30% threshold so they would then switch for the fifth dose to receive Jevtana (cabazitaxel) for the remainder of their chemotherapy.

The interesting thing that we found in both treatment arms was that the chance that a patient had a favorable PSA response, which was defined as a 50% or more decrease, was higher than we had seen in historical trials using each drug by itself without switching.

To put some numbers on that, we found that there was about a 54% chance that patients would have a 50% reduction in PSA if they had to the opportunity to switch from one chemotherapy to the other, compared to about a 45% chance of PSA reduction in the historical data where patients did not switch.
“Patients who are beginning their first chemotherapy should discuss this trial with their oncologist.”

This is not what we found. We found that in both directions, both from the Taxotere (docetaxel) to Jevtana (cabazitaxel) switch, but also in the Jevtana (cabazitaxel) to Taxotere (docetaxel) switch, there was a significant amount of patients, approximately half, who were salvaged by the crossover therapy. By salvaged, I mean those who did not achieve a 30% PSA reduction with the first drug but did achieve a PSA reduction of 50% or more after crossing over to the second drug. As I mentioned before, this occurred in both directions, both in patients receiving Jevtana (cabazitaxel) after Taxotere (docetaxel) and Taxotere (docetaxel) after Jevtana (cabazitaxel).

Are the side effects of Jevtana (cabazitaxel) a little bit easier to tolerate than the side effects of Taxotere (docetaxel)?

Dr. Antonarakis: Interestingly, the side effects of Jevtana (cabazitaxel) in the published literature indeed appear to be slightly better. In this particular trial, which was very small obviously, they seemed comparable. In other words, we did not see any appreciable difference between the Taxotere (docetaxel) and the Jevtana (cabazitaxel) overall in terms of side effects. Taxotere (docetaxel) had a little bit more neuropathy nerve damage, which Jevtana (cabazitaxel) did not do. On the other hand, Jevtana (cabazitaxel) had a little bit more neutropenia, while the Taxotere (docetaxel) did not.

I would say that when patients receive these agents in a first-line setting, in other words, when they had not received another chemotherapy previously, their side effects were fairly comparable. I don’t think there was a clear signal in terms of one drug being clearly safer than the other.

Does it matter which you get first?

Dr. Antonarakis: From a side effect perspective, they’re both fairly equivalent in terms of tolerability, with slight differences in neutropenia, which is worse with Jevtana (cabazitaxel) and neuropathy, which is worse with Taxotere (docetaxel).

What is the next step? Are you going to run a similar trial with more patients?

Dr. Antonarakis: One question that arises is if this small randomized trial is enough to change practice. Should a community oncologist or urologist give Taxotere (docetaxel) for four doses and wait to see if the patient’s PSA drops by 30% or more? If it doesn’t drop to 30% or more, should he or she switch to Jevtana (cabazitaxel)?

I have to admit that this is something that I have done in my practice a few times, but I really don’t believe that this is ready for clinical practice yet. Yes, in this trial, we showed that the PSA response rates could potentially be improved by this switch strategy. What we did not demonstrate was whether this improves overall survival.

The ultimate question is does switching chemotherapy agents after four doses improve survival, compared to just waiting until we see radiographic or clinical progression to switch agents. That would, as you mentioned, require a larger Phase III randomized study. The idea of study design would be to randomize patients to the switch strategy versus no-switch. We would randomize one group of patients to receive chemotherapy and switch if their PSA did not drop by 30%. The second group of patients would start chemotherapy but would not be given the opportunity to switch, even if their PSA did not drop by 30% or more. The randomization would not necessarily be the randomization to the chemotherapy, but would be randomization to a switch strategy versus a stick-with-the-first-chemotherapy strategy.

Sanofi, which makes both Jevtana (cabazitaxel) and Taxotere (docetaxel), have not been eager eager to respond to such a study because of financial considerations and also because the patent life of Taxotere (docetaxel) is over and the patent life of Jevtana (cabazitaxel) will be expiring soon.

Unfortunately, we might be left with a Phase II study that may, potentially, not translate into a Phase III study. I think individual patients and individual oncologists may look at these data and might be convinced that some patients might potentially benefit from a switch strategy, especially those who did not have any degree of PSA reduction after four cycles.

An added complexity is that the popularity of chemotherapy is going down over time and the availability of non-chemotherapy agents is going up. A lot of these patients who may not have a 30% PSA reduction with one chemotherapy, might choose to do another hormone therapy, a radiopharmaceutical drug like Xofigo (radium-223), immunotherapy like Provenge (sipuleucel-T), or even a PARP inhibitor.

It might be difficult to convince a patient who has just failed one chemotherapy after four doses to go immediately to a second chemotherapy. I’m not 100% sure what patients will want. I also don’t think this is a trial that we could have conducted today.

What would you say to a man reading it? That this is worth talking to his oncologist about or is this just something interesting for him to know about?

Dr. Antonarakis: Patients who are beginning their first chemotherapy should discuss this trial with their oncologist, and together with the oncologist decide in a joint fashion whether switching from one chemotherapy agent to another after four doses might be right for him, especially if he’s tolerating the chemotherapy well. If he tolerates the drug and his PSA has not dropped by 30% or is continuing to increase, then in my opinion rather than continue with the potentially futile therapy, a patient and his oncologist may wish to consider using this trial to guide or justify their choice of switching drugs earlier rather than later.
Vitamin C and Combining Taxotere (Docetaxel)

Clinical Trial: Combining Taxotere (Docetaxel) and Vitamin C

Dr. Channing Paller, an Assistant Professor of Oncology at Johns Hopkins University School of Medicine, focuses on translational research and clinical trials of developmental therapeutics in prostate and other solid tumors.

She is keenly interested in the rigorous evaluation of natural products in cancer treatment.

Prostatepedia spoke to her about her Prostate Cancer Foundation instigated and Marcus Foundation-funded clinical trial on combining intravenous Vitamin C with Taxotere (docetaxel).

Why did you become a doctor? What is it about medicine that keeps you interested?

Dr. Channing Paller: In high school, I had a wonderful biology teacher named Melanie Fields who saw something in me and recommended me for a part-time research position at the National Institutes of Health. I did my senior project in an NIH lab where I saw how Vitamin C could be an antioxidant agent by causing differentiation of breast cancer cells.

Between that and other projects, in which I got to work with very advanced confocal microscopes, I began to think that we might cure cancer one day. I know now that curing cancer in the lab is 100 times easier than curing it in humans, but the NIH experiences excited me and persuaded me that hope was on the horizon.

What an exciting project for a high school student. That’s unusual.

Dr. Paller: Julia Barsony, the lab director at NIH, was a great mentor. She believed that young people could be better in the lab than other people because they would “tell it like it is.” Under one of the confocal microscopes once, I found that two genes had mutated in one of her cell lines, but others in the lab weren’t aware of it. Instead of seeing what they thought I should see, I saw what I saw, and I told it like I saw it.

Beginner’s mind.

Dr. Paller: Exactly.

Have you had any particular patients whose cases have changed how you see your role as a doctor?

Dr. Paller: Early in my career, I had a 60-year-old patient who had Stage IV lung cancer. It had taken over her entire left lung. She was given chemotherapy by another physician and had experienced every side effect you could imagine, from hair loss to extreme nausea and vomiting. She came to me for a second opinion. She was a non-smoker, which gave me a clue that her cancer might respond to some new therapies. She refused standard-of-care chemotherapy because of the terrible side effects.

In a sense, we’re curing cancer one percent at a time, as each new validated biomarker that identifies a treatable cancer allows us to extend and improve the quality of the lives of another small segment of the patient population. Finding those biomarkers is a large part of my research focus at Johns Hopkins.

Can you explain the thinking behind your trial on combining Taxotere (docetaxel) with ascorbic acid? Why ascorbic acid and Taxotere (docetaxel)?

Dr. Paller: One of my interests is intravenous Vitamin C, that people take as dietary supplements. We don’t know whether they work or whether they cause harm, so I test them. Several of my clinical trials study these compounds rigorously in a placebo-controlled fashion, as we would with any cancer treatment.

I knew about a recent randomized study of high dose intravenous ascorbic acid (vitamin C) in ovarian cancer patients, which showed that ascorbic acid treatment combined with standard chemotherapy reduced toxicities from the chemotherapy and also tended towards improved overall survival. Vitamin C enabled the patients to receive more cycles of chemotherapy, and it was associated with longer overall survival.

In response to the findings in ovarian cancer, the Prostate Cancer Foundation sent out a request for proposals for early stage research on vitamin C’s role in treating prostate cancer. We decided to initiate a large (60 patient) placebo-controlled trial with co-primary endpoints of quality of life and cancer response to the combination of intravenous (IV) vitamin C and chemotherapy. We are extremely grateful to the Marcus Foundation for supporting the trial.

We chose Taxotere (docetaxel) because it was first line and an easy place to start to answer the question. Jevtana (cabazitaxel) would have worked just as well.

What can you expect to happen during the trial?

Dr. Paller: We are conducting a randomized placebo-controlled Phase II trial of standard-of-care Taxotere (docetaxel) for metastatic castrate-resistant prostate cancer with either ascorbic acid or placebo, which is electrolytes and hydration, given twice a week in between the cycles of chemotherapy every three weeks.

Some people say that this is too big a commitment, so they get to take breaks if needed. They can miss a session or two here or there. They can even take two weeks’ break, if needed. We’re trying to help people live better, not chain them to the clinic.

Are there any specific eligibility criteria that men should be aware of?

Dr. Paller: Sixty-three.

In Annapolis. We are open to adding to some new therapies. We’re trying to help people live better, not chain them to the clinic.

Are there any specific eligibility criteria that men should be aware of?

Dr. Paller: We’re looking for metastatic castrate-resistant prostate cancer patients who are eligible for Taxotere (docetaxel). They should have normal kidney function because the kidneys are required to process the high doses of intravenous Vitamin C.

What about cost?

Dr. Paller: It should be free to patients. Insurance companies pay for the chemotherapy. The clinical
trial pays for anything that is beyond standard of care.

If someone is interested in participating, should they contact you directly?

Dr. Paller: We’d be delighted to see them. Patients can contact me directly or they can go to www.clinicaltrials.gov and search for the clinical trial number: NCT02516670, or link to https://clinicaltrials.gov/ct2/show/NCT02516670. There, they will find emails and phone numbers for every site.

If you reach your endpoint with Taxotere (docetaxel), would you want to repeat this trial with Jevtana (cabazitaxel)?

Dr. Paller: If we see a difference, vitamin C could be added to other chemotherapies, absolutely.

Is there anything else you want patients to know, either about this trial or about the thinking that led to this trial?

Dr. Paller: This study matters. We know that each year complementary medicine practitioners administer more than 350,000 doses of intravenous ascorbic acid to treat more than 10,000 patients with cancer infections and other conditions. We have data on industry sales showing even more.

This trial is essential to let us know whether vitamin C in these high doses is safe, and whether it works. If it does work, we can ask insurance companies to consider paying for it as opposed to patients paying for it out-of-pocket. If it works, this shouldn’t be a therapy exclusively for the rich.

How To Get Involved…

For more information, email Dr. Channing Paller at cpaller1@jhmi.edu.
Bill R. found out he had prostate cancer about a year and a half ago. He's been on Taxotere (docetaxel) and has just started Jevtana (denosumab). At the same time, he took testosterone, and Xgeva (leuprolide), which suppresses the testosterone, and both of them are effective. It takes a while to internalize it, and the first question you ask is: how long have I got? In the beginning, I didn't realize that, so I didn't go out and pound the pavement or anything. In retrospect, it was hard for me to internalize it, and the first question you ask is: how long have I got? I was swimming half a mile per day and more. I figured I had the strength in my body to get through this. Through the first three or four treatments of chemo, I had some of the usual effects, like constipation, occasional nausea, and stuff like that. I took a probiotic during treatment. That seemed to help. Other than that, I really didn't have much of a problem, although, each chemo session beats you further down into the dirt. It's once every three weeks, so you get weaker as you go through it. Right, of course.

Bill R: It was a surprise, certainly not expected. It takes a while to internalize it, and the first question you ask is: how long have I got? That's like asking how to push a piece of string uphill. Nobody really knows the answer. They said that it's very aggressive and, without treatment, probably two years or less.

Bill R: They were going to do six chemo sessions, but my PSA just would not come down. They had expected it to drop close to zero, and we got down in the 20s, but that's about where it ended up.

Bill R: Taxotere (docetaxel).

Bill R: Yes. I started swimming again and working out. When I did the Provenge (sipuleucel-T) in the summer, that wasn't so bad, I guess. It's something that most people don't want to go through—let me put it that way. There were days I was extremely tired and didn't feel well. I was able to get back on my feet, exercise, and lead a normal life. Doing that again, with what I know now, it probably would have been less of an impact on me. That's the challenge for a lot of people. You go into this, and you don't know what you don't know. The doctors don't know what they don't know, and you don't know what you don't know. The doctors don't really know how you're going to react to some of this either.

Bill R: Yes. You're doing everything at the same time. I guess, in retrospect, I slowed down and had a few days of downtime. But it didn't stop me from doing what I wanted to do. I went out and bought a custom chopper motorcycle, and after my Provenge (sipuleucel-T) treatment in the summer, I took a 3,500-mile ride up to Sturgis, out through Yellowstone, and home. Two weeks later, we spent a month in Europe.

Bill R: Yes. You're doing everything at the same time. I guess, in retrospect, I slowed down and had a few days of downtime. But it didn't stop me from doing what I wanted to do. I went out and bought a custom chopper motorcycle, and after my Provenge (sipuleucel-T) treatment in the summer, I took a 3,500-mile ride up to Sturgis, out through Yellowstone, and home. Two weeks later, we spent a month in Europe. It was hard for me, but maybe it wasn't as hard on me as it might have been on others, simply because I was in pretty good shape when I started. If you're not in good shape, it could be tougher.

Right, because everybody is different.

Bill R: Yes. I started swimming again and working out. When I did the Provenge (sipuleucel-T) in the summer, that wasn't so bad, I guess. It's something that most people don't want to go through—let me put it that way. There were days I was extremely tired and didn't feel well. I was able to get back on my feet, exercise, and lead a normal life. Doing that again, with what I know now, it probably would have been less of an impact on me. That's the challenge for a lot of people. You go into this, and you don't know what you don't know. The doctors don't really know how you're going to react to some of this either.

Bill R: Yes. I started swimming again and working out. When I did the Provenge (sipuleucel-T) in the summer, that wasn't so bad, I guess. It's something that most people don't want to go through—let me put it that way. There were days I was extremely tired and didn't feel well. I was able to get back on my feet, exercise, and lead a normal life. Doing that again, with what I know now, it probably would have been less of an impact on me. That's the challenge for a lot of people. You go into this, and you don't know what you don't know. The doctors don't really know how you're going to react to some of this either.

Bill R: Yes. I started swimming again and working out. When I did the Provenge (sipuleucel-T) in the summer, that wasn't so bad, I guess. It's something that most people don't want to go through—let me put it that way. There were days I was extremely tired and didn't feel well. I was able to get back on my feet, exercise, and lead a normal life. Doing that again, with what I know now, it probably would have been less of an impact on me. That's the challenge for a lot of people. You go into this, and you don't know what you don't know. The doctors don't really know how you're going to react to some of this either.

Bill R: Yes. I started swimming again and working out. When I did the Provenge (sipuleucel-T) in the summer, that wasn't so bad, I guess. It's something that most people don't want to go through—let me put it that way. There were days I was extremely tired and didn't feel well. I was able to get back on my feet, exercise, and lead a normal life. Doing that again, with what I know now, it probably would have been less of an impact on me. That's the challenge for a lot of people. You go into this, and you don't know what you don't know. The doctors don't really know how you're going to react to some of this either.

Bill R: Yes. I started swimming again and working out. When I did the Provenge (sipuleucel-T) in the summer, that wasn't so bad, I guess. It's something that most people don't want to go through—let me put it that way. There were days I was extremely tired and didn't feel well. I was able to get back on my feet, exercise, and lead a normal life. Doing that again, with what I know now, it probably would have been less of an impact on me. That's the challenge for a lot of people. You go into this, and you don't know what you don't know. The doctors don't really know how you're going to react to some of this either.

Bill R: Yes. I started swimming again and working out. When I did the Provenge (sipuleucel-T) in the summer, that wasn't so bad, I guess. It's something that most people don't want to go through—let me put it that way. There were days I was extremely tired and didn't feel well. I was able to get back on my feet, exercise, and lead a normal life. Doing that again, with what I know now, it probably would have been less of an impact on me. That's the challenge for a lot of people. You go into this, and you don't know what you don't know. The doctors don't really know how you're going to react to some of this either.

Bill R: Yes. I started swimming again and working out. When I did the Provenge (sipuleucel-T) in the summer, that wasn't so bad, I guess. It's something that most people don't want to go through—let me put it that way. There were days I was extremely tired and didn't feel well. I was able to get back on my feet, exercise, and lead a normal life. Doing that again, with what I know now, it probably would have been less of an impact on me. That's the challenge for a lot of people. You go into this, and you don't know what you don't know. The doctors don't really know how you're going to react to some of this either.

Bill R: Yes. I started swimming again and working out. When I did the Provenge (sipuleucel-T) in the summer, that wasn't so bad, I guess. It's something that most people don't want to go through—let me put it that way. There were days I was extremely tired and didn't feel well. I was able to get back on my feet, exercise, and lead a normal life. Doing that again, with what I know now, it probably would have been less of an impact on me. That's the challenge for a lot of people. You go into this, and you don't know what you don't know. The doctors don't really know how you're going to react to some of this either.
Staying active will make you feel better, even if it's just going out for a walk every day, so you're not sitting there thinking, "I'm going to die, and this is awful."

Right. It's not good for anyone to dwell on that.

Bill R: Right. As soon as you head down that path, you're toast. You've got to find a way to live your life. It forces you to get all your affairs in order because you realize that you're going to pass away before you expect to.

I'm starting Jevtana (cabazitaxel) in a few months because the cancer has progressed.

Bill R: That's what they're telling me, that I shouldn't expect things like water retention and so on. I am going through that now, so the doses are once every three weeks for six rounds. We'll see how that goes.

But it is what it is. I tell everybody if you live long enough, you're going to get prostate cancer.

That's actually true.

Bill R: It's only a question of when. If you get it like I did, earlier in life, it shortens your life. But if you get it when you're 90, nobody knows and nobody cares. Hopefully I've helped people a little bit.

A lot of it is mental. If you swear that this is going to be miserable, everything you look at will contribute to that feeling. Whereas, if you're determined to get through it with a positive attitude, it's not as bad. There's a lot in the mental side that really helps you get through it.
Us TOO: Mark Slaughter’s Prostate Cancer Story

Mark and Denise Slaughter talk about their experience with chemotherapy for prostate cancer.

The C word. No one can imagine beforehand the horror of being told you have cancer.

My problems began with urinary troubles: middle of the night urges, frequency, and the inability to go, start, or finish a urine stream. My primary care physician recommended a urologist.

My urologist was awesome and earned my confidence and trust with his approach. He explained he was trying to see a picture rather like a jigsaw puzzle, but in order to see the picture clearly, he needed more pieces of the puzzle. He convinced me to let him do a digital rectal exam (DRE).

There is no cure. But we can manage early chemotherapy treatment combined with hormone therapy for the treatment of advanced metastatic prostate cancer.

My doctor said that the next step needed to be CT and bone scans that, together, would show us where the cancer had spread in my body.

My next stop was the hospital for the scans. The procedures were simple and easy enough. The results were another story.

February 8, 2018 is a day emblazoned in my memory, a day I will never forget, the day time stopped. That was the day I was told I have the big C word: I have cancer. My doctor was tactful but did not mince words. The CT scan showed cancer in my lymph nodes, in my groin, and up my back on both sides of my spine. The bone scan showed lesions in four places on my pelvis, six places on my ribs. The tests all showed that I have advanced Stage IV metastatic prostate cancer. There is no cure. But we can manage it with hormone treatments and chemotherapy. With no treatment, I might only have a couple of years to live. With treatments, perhaps three to five years.

Upon hearing this news, my first thought was: I am dead. I had been standing next to my wife Denise, white as we listened on the speakerphone. I collapsed into a seated position on the floor and reached out to catch Denise as she fell out of her chair. We crumbled to the floor together, sobbing and wailing with wrenching heaves of our chests. Squeezing each other as though life had ended that very moment. We embraced. We cried. We wept. Time stopped.

We laid together in a heap on the floor for a long time. By the time we climbed to our feet, we could hardly breathe. My face hurt from all the tears. Our eyes were swollen, our noses red below our eyes and otherwise colorless as though life itself had drained from our faces. It was like our lives were over.

My doctor referred us to an oncologist. We couldn’t bear him. He was rude and dismissive as he explained the chemo treatment plans and the poor prognosis for the remainder of my life. It is an understatement to say that he lacked a good bedside manner. Several friends immediately recommended we get a second opinion.

A friend of mine, and my former second opinion. Several friends immediately recommended we get a second opinion. A friend of mine, and my former second opinion. Several friends immediately recommended we get a second opinion.

February 8, 2018 is a day emblazoned in my memory, a day I will never forget, the day time stopped. That was the day I was told I have the big C word: I have cancer. My doctor was tactful but did not mince words. The CT scan showed cancer in my lymph nodes, in my groin, and up my back on both sides of my spine. The bone scan showed lesions in four places on my pelvis, six places on my ribs. The tests all showed that I have advanced Stage IV metastatic prostate cancer. There is no cure. But we can manage it with hormone treatments and chemotherapy. With no treatment, I might only have a couple of years to live. With treatments, perhaps three to five years.

Upon hearing this news, my first thought was: I am dead. I had been standing next to my wife Denise, white as we listened on the speakerphone. I collapsed into a seated position on the floor and reached out to catch Denise as she fell out of her chair. We crumbled to the floor together, sobbing and wailing with wrenching heaves of our chests. Squeezing each other as though life had ended that very moment. We embraced. We cried. We wept. Time stopped.

We laid together in a heap on the floor for a long time. By the time we climbed to our feet, we could hardly breathe. My face hurt from all the tears. Our eyes were swollen, our noses red below our eyes and otherwise colorless as though life itself had drained from our faces. It was like our lives were over.

My doctor referred us to an oncologist. We couldn’t bear him. He was rude and dismissive as he explained the chemo treatment plans and the poor prognosis for the remainder of my life. It is an understatement to say that he lacked a good bedside manner. Several friends immediately recommended we get a second opinion.

A friend of mine, and my former second opinion. Several friends immediately recommended we get a second opinion.

Then the results came. Of the 12 needle biopsy locations, nine were found to contain high-grade cancer. Of those nine, eight had a Gleason score of 8, and the last one was scored at 7. The range for cancer is 6 to 10, so we knew this was a bad score. It meant the cancer had spread beyond the prostate gland.

My doctor said that the next step was to get CT and bone scans that, together, would show where the cancer had spread in my body.

My next stop was the hospital for the scans. The procedures were simple and easy enough. The results were another story.

February 8, 2018 is a day emblazoned in my memory, a day I will never forget, the day time stopped. That was the day I was told I have the big C word: I have cancer. My doctor was tactful but did not mince words. The CT scan showed cancer in my lymph nodes, in my groin, and up my back on both sides of my spine. The bone scan showed lesions in four places on my pelvis, six places on my ribs. The tests all showed that I have advanced Stage IV metastatic prostate cancer. There is no cure. But we can manage it with hormone treatments and chemotherapy. With no treatment, I might only have a couple of years to live. With treatments, perhaps three to five years.

Upon hearing this news, my first thought was: I am dead. I had been standing next to my wife Denise, white as we listened on the speakerphone. I collapsed into a seated position on the floor and reached out to catch Denise as she fell out of her chair. We crumbled to the floor together, sobbing and wailing with wrenching heaves of our chests. Squeezing each other as though life had ended that very moment. We embraced. We cried. We wept. Time stopped.

We laid together in a heap on the floor for a long time. By the time we climbed to our feet, we could hardly breathe. My face hurt from all the tears. Our eyes were swollen, our noses red below our eyes and otherwise colorless as though life itself had drained from our faces. It was like our lives were over.

My doctor referred us to an oncologist. We couldn’t bear him. He was rude and dismissive as he explained the chemo treatment plans and the poor prognosis for the remainder of my life. It is an understatement to say that he lacked a good bedside manner. Several friends immediately recommended we get a second opinion.

A friend of mine, and my former second opinion. Several friends immediately recommended we get a second opinion.
Another side effect: hair loss. I have had heavy, patchy hair loss on my head that started about 13 days after my first chemo treatment. The afternoon when large patches of hair began falling out into my hands in the shower, I decided to take action. The next morning, slowly, deliberately, I dressed, collected my wallet and keys, walked to the garage, got in the car, drove to the nearest barber and got a buzz cut. I didn't think about it. I just did it. And it was one of the best decisions I have made. It is far easier to manage quarter inch long hair than patches of messy hair. I would say to any guy, wait and see if your hair begins to fall out, then just accept the fact and manage it.

As for sexual function, I am 66 years old and have suffered from erectile dysfunction for six or seven years. Hormone therapy is medical castration. The result is loss of sexual function. I rarely have any kind of erection, and even the size of my genitals has shrunk somewhat. But, with a loving partner, these things have not been so hard to accept. I still have the good feelings two people share in intimacy. I would rather be alive than fully-functional, sexually. I do admit my history has made this easier to accept than it might be for some younger men. The key here is perspective. Some choices in life are just hard. You have to decide what matters the most. The biggest positive about chemo is that you do it and it's over forever. For me, six cycles of three weeks, then never again. This compared to a lifetime of multiple pills on a daily basis, worrying all the time about how long they might be effective. On the down side, you have to get your head around walking into a room feeling good and letting them inject you with strong chemicals that will make you feel bad. It’s rather bizarre. I live about 200 miles from my cancer treatment center, so the car trip and hotel stay give me way too much time to let bad thoughts get in the way before each treatment. Again, it’s all about controlling your thoughts and attitude. I know it sounds trite, but holding onto a positive attitude really matters.

The routine at each treatment is: a lab test for blood markers, doctor appointment, and chemo infusion. If my blood looks good, the doctor approves the chemo, then the chemo is prepared and infused. I know it’s working because the blood tests show positive results. My PSA has dropped from 259 to 20, 5, 2, and 1.7 over the first 4 treatments. Similarly, my testosterone has dropped from around 500 to less than 20, which the doctors consider insignificant. They tell me my testosterone level is that of a prepubescent boy, which is good because loss of testosterone starves the cancer.

My oncologist has not even discussed AR-V7 biomarkers with me because, so far, my cancer has been responsive to chemo. We have had some general discussions about castrate-resistant prostate cancer and that there are other options for continued hormone treatments after the Lupron (leuprolide), should it become ineffective.

I have a wonderful support group. First, my loving wife of 46 years is a registered nurse and the best advocate anyone could ever ask for. Second, I live in an active adult community of residents over 55. So many of my neighbors have been supportive and shared their own experiences with cancer. Third, I have a strong faith. My church friends have been amazing with calls, cards, food, gifts, and time for visits. It has been humbling to see how many dear friends I have and how supportive they are in my time of need. I think this is one of the biggest keys in getting through cancer.

I have to mention some of the person-to-person connections I have been provided with through Us TOO have helped greatly in terms of information and support.

My advice to anyone facing chemotherapy is to first go to the nearest national cancer center, get a top-rated oncologist who specializes in your particular cancer, ask questions, listen to suggestions, and make a shared decision with your oncologist and caregiver. Ask your team of doctors and pharmacologists for all information about drugs and their most common side effects. Each person’s cancer is unique and your responses to drugs will also be unique.

The Grim Reaper follows us all. Most of our lives we ignore the inevitable fact that everyone will die. With a chronic, terminal diagnosis, the Grim Reaper comes up closer behind us. The key to survival is to never look back. Focus forward. Look to the light of day. Focus on the here and now. Enjoy life.

In a strange way, having advanced Stage IV metastatic prostate cancer is a gift. It has changed the focus of my life in positive ways. Because now, more than ever before, I live in the present. And life is more intense, fuller, and more complete than I could have imagined.
Combat advanced prostate cancer after treatment with docetaxel.

An option today for TOMORROW’S OPPORTUNITIES

*In the clinical study, among 378 men who received JEVTA, median overall survival was 15.1 months, versus 12.7 months among 377 men who received mitoxantrone.

1The median overall survival is the time, when 50% of the patients who receive a certain treatment are still alive.

Who is JEVTA for?

JEVTANA is a prescription anti-cancer medicine used with the steroid medicine prednisone. JEVTA is used to treat men with castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone) that has worsened (progressed) after treatment with other medicines, including docetaxel.

Important Safety Information

JEVTANA may cause serious side effects, including:

- Low white blood cells, which can cause you to get serious infections, and may lead to death. Men who are 65 years or older may be more likely to have these problems. Your healthcare provider (HCP):
  - will do blood tests regularly to check your white blood cell counts during your treatment with JEVTA.
  - may lower your dose of JEVTA, change how often you receive it, or stop JEVTA until your HCP decides that you have enough white blood cells.
  - may prescribe a medicine for you called G-CSF, to help prevent complications if your white blood cell count is too low.

What is most important to know about JEVTA?

Tell your HCP right away if you have any of these symptoms of infection during treatment with JEVTA: fever (take your temperature often during treatment with JEVTA), cough, burning during urination, or muscle aches. Also, tell your HCP if you have any diarrhea during the time that your white blood cell count is low. Your HCP may prescribe treatment for you as needed.

Severe allergic reactions can happen within a few minutes after your infusion of JEVTA starts, especially during the first and second infusions. Your HCP should prescribe medicines before each infusion to help prevent severe allergic reactions.

Tell your HCP right away if you have any of these symptoms of a severe allergic reaction during or soon after an infusion of JEVTA: rash or itching, skin redness, feeling dizzy or faint, breathing problems, chest or throat tightness, or swelling of face.

JEVTANA can cause severe stomach and intestine problems, which may lead to death. You may need to go to the hospital for treatment.

Vomiting and diarrhea can happen when you receive JEVTA. Severe vomiting and diarrhea with JEVTA can lead to loss of too much body fluid (dehydration), or too much of your body salts (electrolytes). Death has happened from having severe diarrhea and losing too much body fluid or body salts with JEVTA. Your HCP will prescribe medicines to prevent or treat vomiting and diarrhea, as needed with JEVTA.

Tell your HCP if you have vomiting or diarrhea, or if your symptoms get worse or do not get better. JEVTA can cause a leak in the stomach or intestine, intestinal blockage, infection, and bleeding in the stomach or intestine. This can lead to death. Tell your HCP if you get any of these symptoms: severe stomach-area (abdomen) pain, constipation, fever, blood in your stool, or changes in the color of your stool.

Kidney failure may happen with JEVTA, because of severe infection, loss of too much body fluid (dehydration), and other reasons, which may lead to death. Your HCP will check you for this problem and treat you if needed.

Tell your HCP if you have vomiting or diarrhea, or if your symptoms get worse or do not get better. JEVTA can cause a leak in the stomach or intestine, intestinal blockage, infection, and bleeding in the stomach or intestine. This can lead to death. Tell your HCP if you get any of these symptoms: severe stomach-area (abdomen) pain, constipation, fever, blood in your stool, or changes in the color of your stool.

Tell your HCP if you have trouble breathing, shortness of breath, chest pain, cough or fever.

Tell your HCP if you develop these signs or symptoms:

- swelling of your face or body, or decrease in the amount of urine that your body makes each day or blood in your urine.

Tell your HCP if you develop any new or worsening symptoms, including: trouble breathing, shortness of breath, chest pain, cough or fever.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Please see Important Safety Information on next page.

Please see additional Important Safety Information and the Brief Summary on the following pages.
Important Safety Information—continued

Who should not receive JEVTANA?

Do not receive JEVTANA if:

• you have vomiting or diarrhea
• you have symptoms that are worse or do not get better
• JEVTANA can cause a leak in the stomach or intestine, intestinal blockage, infection, and bleeding in the stomach or intestine. This can lead to death.
• Tell your healthcare provider if you get any of these symptoms:
  • severe stomach-area (abdomen) pain
  • constipation
  • fever
  • blood in your stool, or changes in the color of your stool
• Kidney failure. Kidney failure may happen with JEVTANA, because of severe infection, loss of too much body fluid (dehydration), and other reasons, which may lead to death.
• Your healthcare provider will check you for this problem and treat you if needed.

Tell your healthcare provider if you develop these signs or symptoms:

• swelling of your face or body
• decrease in the amount of urine that your body makes each day
• blood in your urine

Lung or breathing problems. Lung or breathing problems may happen with JEVTANA and may lead to death. Men who have lung disease before receiving JEVTANA may have a higher risk for developing lung or breathing problems with JEVTANA treatment. Your healthcare provider will check you for this problem and treat you if needed.

Tell your healthcare provider right away if you develop any new or worsening symptoms, including: trouble breathing, shortness of breath, chest pain, cough, or fever.

What is JEVTANA?

JEVTANA is a prescription anti-cancer medicine used with the steroid medicine prednisone. JEVTANA is used to treat men with castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone) that has worsened (progressed) after treatment with other medicines that included docetaxel.

JEVTANA is not for use in females.

It is not known if JEVTANA is safe and effective in children.

Who should not receive JEVTANA?

Do not receive JEVTANA if:

• your white blood cell (neutrophil count) is too low
• you have had a severe allergic reaction to cabazitaxel or other medicines that contain polysorbate 80 (ask your HCP if you are not sure), you have severe liver problems or you are pregnant. JEVTANA can harm your unborn baby or possibly cause loss of pregnancy.

What should I tell my HCP before receiving JEVTANA?

Before receiving JEVTANA, tell your HCP if you:

• have had allergic reactions in the past
• are age 65 or older
• have kidney or liver problems
• have lung problems
• are a male with a female partner who is able to become pregnant. Males should use effective birth control (contraception) during treatment with JEVTANA and for 3 months after your final dose of JEVTANA.

JEVTANA may cause fertility problems in males. This may affect your ability to father a child. Talk to your HCP if you have concerns about fertility.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. JEVTANA can interact with many other medicines. Do not take any new medicines without asking your HCP first. Your HCP will tell you if it is safe to take the new medicine with JEVTANA.

What are the possible side effects of JEVTANA?

Common side effects of JEVTANA include:

• low red blood cell count (anemia) is common with JEVTANA, but can sometimes also be serious. Your HCP will regularly check your red blood cell count. Symptoms of anemia include shortness of breath and tiredness.
• low blood platelet count is common with JEVTANA, but can sometimes also be serious. Tell your HCP if you have any unusual bruising or bleeding.
• numbness, tingling, burning or decreased sensation in your hands or feet
• blood in your urine. Tell your HCP if you see blood in your urine
• fever
• diarrhea
• tiredness
• nausea
• vomiting
• constipation
• weakness
• stomach pain

Tell your HCP if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of JEVTANA. For more information, ask your HCP or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Important Safety Information

What is the most important information I should know about JEVTANA?

JEVTANA may cause serious side effects including:

Low white blood cells. Low white blood cells can cause you to get serious infections, and may lead to death. Men who are 65 years or older may be more likely to have these problems. Your healthcare provider:
• will do blood tests regularly to check your white blood cell counts during your treatment with JEVTANA.
• may lower your dose of JEVTANA, change how often you receive it, or stop JEVTANA until your healthcare provider decides that you have enough white blood cells.
• may prescribe a medicine for you called G-CSF, to help prevent complications if your white blood cell count is too low.

Tell your healthcare provider right away if you have any of these symptoms of infection during treatment with JEVTANA:
• fever. Take your temperature often during treatment with JEVTANA.
• cough
• burning or irritation
• muscle aches

Also, tell your healthcare provider if you have any diarrhea during the time that your white blood cell count is low. Your healthcare provider may prescribe treatment for you as needed.

Severe allergic reactions. Severe allergic reactions can happen within a few minutes after your infusion of JEVTANA starts, especially during the first and second infusions. Your healthcare provider should prescribe medicines before each infusion to help prevent severe allergic reactions.

Tell your healthcare provider or nurse right away if you have any of these symptoms of a severe allergic reaction during or soon after an infusion of JEVTANA:
• rash or itching
• skin redness
• feeling dizzy or faint
• joint pain
• hair loss
• decreased appetite
• back pain
• change in your sense of taste
• shortness of breath
• cough
• joint pain
• hair loss
• decreased appetite

Tell your HCP if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of JEVTANA. For more information, ask your HCP or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before receiving JEVTANA, tell your healthcare provider about all your medical conditions, including if you:
• had allergic reactions in the past
• are over the age of 65
• have kidney or liver problems
• have lung problems
• are a male with a female partner who is able to become pregnant. Males should use effective birth control (contraception) during treatment with JEVTANA and for 3 months after your final dose of JEVTANA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. JEVTANA can interact with many other medicines. Do not take any new medicines without asking your healthcare provider first. Your healthcare provider will tell you if it is safe to take the new medicine with JEVTANA.

How will I receive JEVTANA?
• JEVTANA will be given to you by an intravenous (IV) infusion into your vein.
• Your treatment will take about 1 hour.
• JEVTANA is usually given every 3 weeks. Your healthcare provider will decide how often you will receive JEVTANA.
• Your healthcare provider will also prescribe another medicine called prednisone for you to take by mouth every day during treatment with JEVTANA. Your healthcare provider will tell you how and when to take your prednisone.

It is important that you take prednisone exactly as prescribed by your healthcare provider. If you forget to take your prednisone, or do not take it on schedule, make sure to tell your healthcare provider or nurse. Before each infusion of JEVTANA, you may receive other medicines to prevent or treat side effects.

What are the possible side effects of JEVTANA? JEVTANA may cause serious side effects including:
• See “What is the most important information I should know about JEVTANA?”

Common side effects of JEVTANA include:
• Low red blood cell count (anemia). Low red blood cell count is common with JEVTANA, but can sometimes also be serious. Your healthcare provider will regularly check your red blood cell count. Symptoms of anemia include shortness of breath and tiredness.
• Low platelet count. Low platelet count is common with JEVTANA, but can sometimes also be serious. Tell your healthcare provider if you have any unusual bruising or bleeding.

• diarrhea
• itchy skin
• nausea
• vomiting
• constipation
• inflammation of the bladder has happened in men who have previously received pelvic radiation therapy. Tell your healthcare provider if you see blood in your urine, burning sensation during urination, or frequent or urgent need to urinate.
• weakness
• stomach (abdominal) pain
• blood in your urine. Tell your healthcare provider or nurse if you see blood in your urine.
• back pain
• decreased appetite
• shortness of breath
• hair loss
• cough

JEVTANA may cause problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of JEVTANA. For more information, ask your pharmacist or healthcare provider for information about JEVTANA that is written for health professionals.

What are the ingredients in JEVTANA?
Active ingredient: cabazitaxel
Inactive ingredient: polysorbate 80
Manufactured by: sanofi-aventis U.S. LLC, Bridgewater, NJ 08807. A SANOFI COMPANY
JEVTANA is a registered trademark of sanofi-aventis © 2017 sanofi-aventis U.S. LLC
For more information, go to www.sanofi-aventis.us or call 1-800-633-1610.
Coming Up!

August:
Erectile Dysfunction After Cancer